Advanced Search
Article Contents
ABOUT THIS ARTICLE
The Innovation Oncology > 2026 Vol. 1 > No. 2 > 100018
Next Article Previous Article
NEWS & BUZZ   Open Access     Cite

Cracking the “undruggable”: Landmark trial sparks hope for fighting “King of Cancers”

More Information
  • Corresponding author: oncology@the-innovation.org
  • Received Date:  June 12, 2026
    Accepted Date:  June 12, 2026
    Published Online:  June 19, 2026
The Innovation Oncology  1(2),  https://doi.org/10.59717/j.xinn-oncol.2026.100018  |  Cite this article
    • FullText(HTML)
  • 加载中
    • REFERENCES
  • [1] O’Reilly E.M., Wainberg Z.A., Hendifar A.E., et al. (2026). Daraxonrasib or chemotherapy in previously treated metastatic pancreatic cancer. N. Engl. J. Med. DOI:10.1056/NEJMoa2605555.

    View in Article Google Scholar

    [2] Der C.J. and Yeh J.J. (2026). Advances in RAS therapeutics for pancreatic cancer. N. Engl. J. Med. 394:1857−1861. DOI:10.1056/NEJMe2600517

    View in Article CrossRef Google Scholar

    • Cited by

  • Cite this article:

    The Innovation Oncology News Team (2026). Cracking the “undruggable”: Landmark trial sparks hope for fighting “King of Cancers”. The Innovation Oncology 1:100018. https://doi.org/10.59717/j.xinn-oncol.2026.100018
    The Innovation Oncology News Team (2026). Cracking the “undruggable”: Landmark trial sparks hope for fighting “King of Cancers”. The Innovation Oncology 1:100018. https://doi.org/10.59717/j.xinn-oncol.2026.100018

Welcome!

To request copyright permission to republish or share portions of our works, please visit Copyright Clearance Center's (CCC) Marketplace website at marketplace.copyright.com.

PDF
Figures(1)    

Share

  • Share the QR code with wechat scanning code to friends and circle of friends.

Article Metrics

Article views(482) PDF downloads(125)

Relative Articles

Cited by

Catalog

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return

    {{newsColumn.name}}

    {{newsColumn.name}}

    Stay connected

    {{newsColumn.name}}

    Website copyright © Innovation Press. Published articles are licensed under CC BY with copyright retained by the authors.